November 11, 2005

INVESTOR CONTACT:

A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com




FOR IMMEDIATE RELEASE

Data From Three New AutoPulse Clinical Studies to be Presented at the American Heart Association Meeting



CHELMSFORD, MASS. -  Friday, November 11, 2005 – ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today that data from three new clinical studies relating to the AutoPulse® Non-invasive Cardiac Support Pump will be presented at the American Heart Association (AHA) Meeting in Dallas.

One presentation, entitled “Case-Control Study of AutoPulse for Out-of-Hospital Cardiac Arrest (Joseph P. Ornato, M.D., Richmond, VA),” will report on AutoPulse use by the Richmond Ambulance Authority. These results are expected to show a positive benefit to use of the AutoPulse on sudden cardiac arrest (SCA) patients.

A second presentation, entitled “Update on ASPIRE Trial of AutoPulse for Out-of-Hospital Cardiac Arrest (Alfred P. Hallstrom, Ph.D., Seattle, WA; Michael R. Sayre, M.D., Columbus, OH),” will report on interim data from the ASPIRE Trial. As previously reported, enrollment in the trial was suspended in March of this year. The data are expected to show equivalent short-term survival when comparing the AutoPulse to manual CPR, but a difference in survival to hospital discharge favoring manual CPR.

The third presentation, entitled “Effect of a CPR Assist Device on Survival to Emergency Department Arrival in Out-of-Hospital Cardiac Arrest (Mark Swanson, EMT-P et al., EVAC Ambulance, FL),” is expected to show that patients receiving chest compressions from the AutoPulse had an increase in short-term survival—defined as delivery to a hospital emergency department alive—compared to manual CPR conducted by trained rescuers.

“These are three important new studies providing a better understanding of AutoPulse and we anticipate that two of them will confirm the value of the AutoPulse in treating cardiac arrest in the field,” said Richard A. Packer, ZOLL’s President and Chief Executive Officer. “The expected report on the ASPIRE Trial will be disappointing because it was not completed, was inconclusive, and presents numerous questions about how best to implement resuscitation studies. We now better understand the challenges of such an effort, and we plan further research.”
Mr. Packer concluded, “While no single study will make or break the acceptance and use of the AutoPulse, resuscitation science clearly favors the AutoPulse, and we continue to believe that it represents a major advancement in resuscitation technology.”

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East, Asia, and Australia.

Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the resuscitation business; acceptance of the AutoPulse; changes in regulations affecting the healthcare industry; general economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Quarterly Report on Form 10-Q, which was filed with the SEC on August 12, 2005.


© 2005 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse is a registered trademark of ZOLL Medical Corporation. All product names are the property of their respective owners.